Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.42 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.41 |
| ▸ | CASP1 | P29466 | 1/20 | 0.41 |
| ▸ | CASP7 | P55210 | 1/20 | 0.41 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | HTT | P42858 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | MAOB | P27338 | 2/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25144720 | 0.87 | ALDH1A1 (0.51) | SMN1; SMN2ALDH1A1KDM4EHSD17B10MAPK1 | |
| SCHEMBL25144727 | 0.86 | SMN1; SMN2 (0.46) | SMN1; SMN2ALDH1A1KDM4EHSD17B10MAPK1 | |
| SCHEMBL19762359 | 0.82 | KDM4E (0.46) | ALDH1A1KDM4EHSD17B10MAPK1MAPT | |
| SCHEMBL25983659 | 0.81 | TDP1 (0.55) | SMN1; SMN2MAPTCHRM2MEN1KMT2A | |
| SCHEMBL25144719 | 0.80 | MAPT (0.46) | SMN1; SMN2ALDH1A1KDM4EHSD17B10MAPK1 | |
| SCHEMBL24671120 | 0.79 | MEN1 (0.44) | ALDH1A1KDM4EHSD17B10MAPTALOX15 | |
| SCHEMBL10022401 | 0.76 | POLB (0.54) | ALDH1A1KDM4EHSD17B10MEN1KMT2A | |
| SCHEMBL10022390 | 0.75 | KDM4E (0.63) | SMN1; SMN2ALDH1A1KDM4EHSD17B10MAPK1 | |
| SCHEMBL2759471 | 0.74 | MAPT (0.63) | SMN1; SMN2MAPTCHRM2MEN1KMT2A | |
| SCHEMBL22021634 | 0.72 | LMNA (0.48) | SMN1; SMN2ALDH1A1KDM4EHSD17B10MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230119227-A1 | OLIGONUCLEOTIDE SYNTHESIS ON SOLID SUPPORT | INTEGRATED DNA TECHNOLOGIES, INC. | 2023-04-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230119227-A1 | OLIGONUCLEOTIDE SYNTHESIS ON SOLID SUPPORT | RNGTT, SSU72, NSUN2 | SMN1; SMN2 364/4885ALDH1A1 3898/4885KDM4E 3547/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.